Exousia Pro Settles Litigation, Eliminating $200K Debt and Cancelling 6.3M Shares
MAJI sits 99% above its 52-week low of $0.015.
Summary
Exousia Pro, Inc. announced a favorable litigation settlement that will significantly improve its financial position. The agreement involves a one-time payment of $147,500 in exchange for the complete cancellation of a $200,000 promissory note and the return of 6,297,511 common shares to treasury. This event follows recent capital structure adjustments, including a prior cancellation of derivative securities and a Regulation A offering. For this micro-cap biotechnology company, the debt elimination and substantial share cancellation are highly material, strengthening the balance sheet, reversing prior dilution, and directly enhancing shareholder value. Traders will be watching how the company leverages this improved financial clarity to advance its clinical pipeline and telehealth initiatives.
At the time of this announcement, MAJI was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.02 to $0.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.